Pas de connexion internet — affichage de la version enregistrée de la page.

Iovance Biotherap…

USUSD
← Vers le Screener
US:IOVALSE:0JDK

Iovance Biotherapeutics Inc (US:IOVA) — Biotechnology: Biological Products (No Diagnostic Substances). Nombre de places boursières sur lesquelles les actions de la société sont cotées : 2. Sur cette page : cours et graphique, dividendes, principaux actionnaires et historique du nombre d'actions.

À propos de l'entreprise

Site Web
iovance.com
Relations avec les Investisseurs
ir.iovance.com/
Secteur
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
Siège Social
San Carlos, United States
PDG
Frederick G. Vogt
Employés
975
Fondée
2007
Actions en Circulation
452.97 M au 2026-07-29
Flottant
394.31 M
Capitalisation Boursière
6.71 Md USD
Initiés
0.35%
Investisseurs Institutionnels
70.68%
Secteur d'Activité (SIC)
Biological Products, (No Diagnostic Substances)
ISIN
US4622601007
LEI
2549002L8WT2ACU5Q878
P/E
perte
FCF
−296 M USD
Dette
1.00 M USD
trésorerie nette
Résultats et FCF — pour les 12 mois à 30.06.2026 (dernier rapport de l'entreprise).
NAV
1.62 USD · P/NAV 9.06
Date du Bilan30.06.2026
Actifs916 M USD
− Passifs179 M USD
= NAV (capitaux propres des actionnaires de la société)736 M USD
− Actifs Incorporels264 M USD
= NAV Tangible472 M USD
Actions452 971 016
NAV par Action1.62 USD
VLV Tangible par Action1.04 USD
Prix de l'Action (IOVA)14.7200 USD
P/NAV9.06
Historique de la NAV
Date du BilanNAVNAV par Action
30.06.2026736 M USD1.62 USD
31.03.2026722 M USD1.65 USD
31.12.2025699 M USD1.70 USD
30.09.2025702 M USD1.82 USD
30.06.2025698 M USD2.04 USD
31.03.2025768 M USD2.30 USD
31.12.2024710 M USD2.33 USD
30.09.2024773 M USD2.54 USD
Description

Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It also develops lifileucel for the treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma (HNSCC); LN-145-S1 to treat melanoma and HNSCC; LN-145 Gen 3 and core biopsy for the treatment of NSCLC; LN-145 Gen 3 to treat melanoma and HNSCC; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001 for use in the TIL therapy treatment regimen. The company has collaborations and licensing agreements with National Institutes of Health; the National Cancer Institute; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

publicité

Bourses et Tickers

BourseTickerDevisePrixType
US USA StocksIOVA principaleUSD14.72 +3.59%actions ordinaires
LSE London Stock Exchange0JDK IOBUSD14.99 +0.00%actions ordinaires

Cours sur 3 Mois

jour de hausse jour de baisseSurvolez / touchez un jour — cours d'ouverture, de clôture, plus haut et plus bas

Principaux Actionnaires

DétenteurParticipationActionsDate du Rapport
Blackrock Inc.8.16%36.96 M2026-06-30
MHR Fund Management, LLC6.39%28.97 M2026-06-30
State Street Corporation5.4%24.48 M2026-06-30
Two Sigma Investments, L…4.2%19.01 M2026-06-30
Vanguard Capital Managem…4.02%18.2 M2026-06-30
SPDR SERIES TRUST-State…3.38%15.3 M2026-08-31
Vanguard Portfolio Manag…3.18%14.39 M2026-06-30
VANGUARD INDEX FUNDS-Van…2.98%13.49 M2026-06-30
Geode Capital Management…2.28%10.32 M2026-06-30
iShares Trust-iShares Ru…2.25%10.2 M2026-08-31
Millennium Management Ll…1.88%8.53 M2026-06-30
Dimensional Fund Advisor…1.43%6.46 M2026-06-30
Palo Alto Investors Lp1.17%5.3 M2026-06-30
VANGUARD INDEX FUNDS-Van…1.07%4.86 M2026-06-30
Fidelity Salem Street Tr…0.96%4.35 M2026-07-31
VANGUARD INDEX FUNDS-Van…0.95%4.31 M2026-06-30
iShares Trust-iShares Ru…0.82%3.71 M2026-08-31
VANGUARD INDEX FUNDS-Van…0.68%3.08 M2026-06-30
iShares Trust-iShares Bi…0.64%2.9 M2026-08-31
TIAA-CREF Funds-Nuveen Q…0.6%2.71 M2026-07-31
VOGT FREDERICK G (Chief…≈0.13%595 4472026-09-08
PURI RAJ K (Officer)≈0.06%256 3642026-09-08
KIRBY DANIEL GORDON (Off…≈0.03%154 5112026-08-10
BILINSKY IGOR P (Chief O…≈0.03%142 0742026-09-08
GRAF FINCKENSTEIN FRIEDR…≈0.03%140 1112026-06-05
BELLEMIN JEAN-MARC (Chie…≈0.01%60 5292025-06-02
ROCHE CORLEEN M (Chief F…≈0.01%28 7572026-08-06
MAYNARD RYAN D (Director…≈0%7 5002024-11-12